{
  "id": 4815904,
  "title": "Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis",
  "url": "https://urgent.news/2026/09/01/boehringer-ingelheim-launches-scovella-in-great-britain-the-first",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T08:04:11.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/boehringer-ingelheim-launches-scovella-in-great-britain-the-first-approved-therapy-for-insulin-dysregulation-in-horses-a-main-cause-of-laminitis"
  },
  "original_language": "en",
  "account": null,
  "summary": "Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies1, targeting the key underlying driver of laminitis.² Studies showed that SCOVELLA® rapidly and significantly reduces hyperinsulinemia with effects showing within days of starting treatment.4,6 Laminitis…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}